Inventor · disambiguated record
Daniel R. Getts
Also filed as: GETTS DANIEL · GETTS DANIEL R
29 granted patents·50 pending applications·107 citations·filing 2010–2025
96Inventor score
Files withMYELOID THERAPEUTICS INC31UNIV NORTHWESTERN20COUR PHARMACEUTICALS DEV COMPANY INC11TCR2 THERAPEUTICS INC5TOLERA THERAPEUTICS INC5
Top patents by PatentIndex Score
79 records- 0196US11026973B2Engineered phagocytic receptor compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2020·Granted Jun 8, 2021·6 cites·16 claims
- 0296US11013764B2Engineered phagocytic receptor compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2020·Granted May 25, 2021·6 cites·14 claims
- 0396US10980836B1Therapeutic cell compositions and methods of manufacturing and use thereofMYELOID THERAPEUTICS INC·Filed 2020·Granted Apr 20, 2021·15 cites·21 claims
- 0495US11389517B2Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2021·Granted Jul 19, 2022·2 cites·22 claims
- 0594US11628218B2Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2022·Granted Apr 18, 2023·3 cites·22 claims
- 0694US11129881B2Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2020·Granted Sep 28, 2021·3 cites·17 claims
- 0793US9616113B2Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2015·Granted Apr 11, 2017·12 cites·13 claims
- 0892US9522180B2Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2015·Granted Dec 20, 2016·10 cites·19 claims
- 0991US11672874B2Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2021·Granted Jun 13, 2023·2 cites·26 claims
- 1090US2025049901A1Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2024·Application pending·0 cites
- 1189US10188711B2Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2016·Granted Jan 29, 2019·5 cites·30 claims
- 1288US12319925B2Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2023·Granted Jun 3, 2025·1 cites·21 claims
- 1388US10617747B2Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2018·Granted Apr 14, 2020·4 cites·42 claims
- 1488US9913883B2Immune-modifying nanoparticles for the treatment of inflammatory diseasesCOUR PHARMACEUTICALS DEV COMPANY·Filed 2014·Granted Mar 13, 2018·9 cites·23 claims
- 1587US8722049B2Antibody and methods for selective inhibition of T-cell responsesTOLERA THERAPEUTICS INC·Filed 2013·Granted May 13, 2014·6 cites·7 claims
- 1686US11510996B2Covalent polymer-antigen conjugated particlesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2016·Granted Nov 29, 2022·3 cites·18 claims
- 1784US11826407B2Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2020·Granted Nov 28, 2023·1 cites·26 claims
- 1884US8524234B2Antibody for selective inhibition of T-cell responsesTOLERA THERAPEUTICS INC·Filed 2012·Granted Sep 3, 2013·8 cites·2 claims
- 1984US2025009858A1Peptide Conjugated ParticlesUNIV NORTHWESTERN·Filed 2024·Application pending·0 cites
- 2082US11413337B2Peptide conjugated particles for the treatment of inflammationUNIV NORTHWESTERN·Filed 2019·Granted Aug 16, 2022·2 cites·12 claims
- 2182US10201596B2Peptide conjugated particles for the treatment of allergyUNIV NORTHWESTERN·Filed 2013·Granted Feb 12, 2019·4 cites·21 claims
- 2282US2024000830A1Immune-modifying nanoparticles for the treatment of inflammatory diseasesONCOUR PHARMA INC·Filed 2023·Application pending·0 cites
- 2379US11944680B2Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2023·Granted Apr 2, 2024·0 cites·20 claims
- 2479US2023364265A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2578US2024245719A1Modified immune-modulating particlesONCOUR PHARMA INC·Filed 2023·Application pending·0 cites
- 2678US2024252630A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2776US9919005B2Immune-modifying nanoparticles for the treatment of inflammatory diseasesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2016·Granted Mar 20, 2018·1 cites·17 claims
- 2875US10471093B2Modified immune-modulating particlesCOUR PHARMACEUTICALS DEV COMPANY·Filed 2015·Granted Nov 12, 2019·2 cites·9 claims
- 2975US2022411817A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3075US2022364110A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3175US2024391998A1Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3274US11484506B2Process for the preparation of tolerizing immune-modulating particlesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2017·Granted Nov 1, 2022·1 cites·27 claims
- 3374US2022273778A1Method of inducing antigen-specific tolerance in a subject by administering a composition comprising an apoptotic body surrogate and coupled immunodominant antigenic epitopes associated with autoimmune diseaseUNIV NORTHWESTERN·Filed 2021·Application pending·0 cites
- 3474US2022184230A1Methods and compositions for genomic integrationMYELOID THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3573US12502436B2Covalent polymer-antigen conjugated particlesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2022·Granted Dec 23, 2025·0 cites·20 claims
- 3673US2021000932A1Peptide Conjugated ParticlesUNIV NORTHWESTERN·Filed 2020·Application pending·0 cites
- 3772US12030938B2Engineered chimeric fusion protein compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2023·Granted Jul 9, 2024·0 cites·30 claims
- 3872US11020424B2Modified immune-modulating particlesONCOUR PHARMA INC·Filed 2018·Granted Jun 1, 2021·1 cites·9 claims
- 3972US2020046816A1Compositions and Methods for Antigen-Specific ToleranceUNIV NORTHWESTERN·Filed 2019·Application pending·0 cites
- 4072US2022143160A1Compositions Comprising Apoptotic Signaling and Methods for Induction of Antigen-Specific ToleranceUNIV NORTHWESTERN·Filed 2022·Application pending·0 cites
- 4172US2024122864A1Particles encapsulating fusion proteins containing linked epitopesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2023·Application pending·0 cites
- 4271US2025387461A1Compositions and methods for antigen-specific toleranceUNIV NORTHWESTERN·Filed 2025·Application pending·0 cites
- 4370US11160851B2Peptide conjugated particlesUNIV NORTHWESTERN·Filed 2017·Granted Nov 2, 2021·0 cites·17 claims
- 4470US2020276228A1Immune-modifying nanoparticles for the treatment of inflammatory diseasesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2020·Application pending·0 cites
- 4570US2020276227A1Immune-modifying nanoparticles for the treatment of inflammatory diseasesCOUR PHARMACEUTICALS DEV COMPANY INC·Filed 2020·Application pending·0 cites
- 4668US2025090663A1Binding domains and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4767US2021299172A1Engineered phagocytic receptor compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4867US2015150996A1Compositions and methods for antigen-specific toleranceUNIV NORTHWESTERN·Filed 2013·Application pending·0 cites
- 4967US2024327482A1Macrophage specific engager compositions and methods of use thereofMYELOID THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 5067US2024148785A1Therapeutic cell compositions and methods for manufacture and uses thereofMYELOID THERAPEUTICS INC·Filed 2023·Application pending·0 cites
Showing the top 50 of 79 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Daniel R. Getts files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →